Immune response
Researchers from the First Affiliated Hospital of Bengbu Medical University have shed light on the role of NUP85 in cancer development, particularly in prostate cancer. According to a new report, NUP85's expression patterns demonstrate significant correlations with the activity of cancer-related pathways and immunological interactions involving macrophages and
Cancer research
Researchers at the Harvey L. Neiman Health Policy Institute have conducted a geospatial cross-sectional analysis to assess the relative importance of community measures for explaining county-level variance in cancer screening, prevalence, and mortality rates for breast, colorectal, lung, and prostate cancers. The study utilized random forest algorithms to estimate the
Cancer treatment
Boston Scientific Scimed Inc. has been issued patent number 12440258 for a novel method of treating prostate cancer, according to a report from NewsRx. The patent, filed on November 20, 2023, and published online on October 14, 2025, describes a method for treating prostate cancer using a vapor delivery needle
Learning strategies
Researchers at the Polytechnic University of Bari in Italy have made significant strides in developing computer-assisted tools for evaluating surgical performance during robot-assisted radical prostatectomy. According to a new study, deep learning strategies have been employed to improve the accuracy of semantic segmentation in robot-assisted radical prostatectomy videos, paving the
Cancer research
A new study on laparoscopic radical prostatectomy (LRP) outcomes has shed light on the importance of preserving the length of the membranous urethra in patients undergoing this type of surgery. The study, conducted by researchers at Linyi Cancer Hospital in Shandong, People's Republic of China, found that patients
Cancer research
As the festive season approaches, the Telegraph is once again launching its Christmas Charity Appeal, a 100-year tradition of supporting those in need through carefully chosen causes. This year, the appeal focuses on four charities: the Motor Neurone Disease Association, Prostate Cancer Research, Canine Partners, and The Not Forgotten. Each
Cancer research
Research conducted in one of the largest European trials found that prostate cancer screening can reduce mortality rates by 13%, with the potential to save around 1,500 lives annually in the UK. The study suggests that a targeted approach to screening is necessary, focusing on those at the greatest
Cancer research
A new study has investigated the impact of Phase-III genitourinary oncology trial endpoint fulfillment (EF+) on FDA approval probability over the past 15 years. Research published in Clinical Genitourinary Cancer found that trials with overall survival EF+ (OS+) had a significantly higher likelihood of FDA approval. The study analyzed 183
Cancer research
A recent study published in JAMA Oncology has shed new light on the optimal treatment strategies for patients with prostate cancer, particularly those with cribriform-positive disease. The study, which analyzed data from the PROTECT randomized clinical trial, found that cribriform-positive disease was associated with a significantly increased risk of metastasis,
Prostate cancer
Research has highlighted the enduring impact of prostate cancer on a man's identity, even years after diagnosis and treatment. A new study published in the journal BMC Geriatrics has shed light on the diverse cancer-related identities exhibited by prostate cancer survivors over the age of 75. The study,
Cancer research
Recent research published in the Journal of Radioanalytical and Nuclear Chemistry by researchers from the Tehran University of Medical Sciences has highlighted the significant advancements in the diagnosis and treatment of prostate cancer in nuclear medicine. The study emphasizes the importance of improved diagnostic capabilities, particularly radiolabeled PSMA PET/CT
Prostate cancer
Thousands of prostate cancer patients will have access to a new and gentler treatment option, with the National Institute for Health and Care Excellence (Nice) recommending the use of darolutamide, also known as Nubeqa, in combination with androgen deprivation therapy (ADT) for men with hormone-sensitive advanced prostate cancer. This decision
